ClinicalTrials.gg
RecruitingNCT07053982ENDO-TEPUpdated Mar 25, 2026

Use of a New Diagnostic Tool in the Detection and Characterization of Endometriosis Lesions

An interventional study of Preoperative [18F]-FES PET/CT Imaging and Estrogen Receptor Expression Analysis in Endometriosis Surgery in Endometriosis, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 128 studies in Endometriosis with a site in France — 51 open to participants now, 56 under way, 1 of them phase 3. Endometriosis · France.

Planned enrollment
61st of 70
20 · median 91
Started
2026
with 14 others
No phase
57 of 128
27 open now
Primary completion
2028-03
later than 42 of 55 live
Registered
106th of 128
by date

Among the 128 studies in Endometriosis with a site in France, this one is the 61st largest by planned enrollment of the 70 interventional ones that give a count, is one of 15 that started in 2026, is one of 57 with no phase, reaches primary completion later than 42 of the 55 other live ones, and was the 106th registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

51 of the 128 studies in Endometriosis with a site in France are open now. Recruiting first, the newest first:

45 more — sign in →

All 51 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Endometriosis with a site in France, or all of them as a file.
02

Study summary

Diagnostic wandering is one of the characteristics of endometriosis due to great anatomical and clinical variability but also due to poorly relevant diagnostic examinations. [18F]-FES PET/CT could on the one hand improve diagnosis by showing greater sensitivity than MRI and on the other hand make it possible to quantify and characterize the expression of ER from diagnosis and thus helping to guide therapeutic care. We will thus attempt to correlate the intensity of [18F]-FES PET/CT with the expression of estrogen receptors and the intensity of pain.

Read the detailed description

Endometriosis is a chronic estrogen-dependent gynecological condition that leads to impaired overall quality of life due to infertility and associated pain. Diagnostic wandering is one of the characteristics of endometriosis due to great anatomical and clinical variability but also due to poorly relevant diagnostic examinations. There are several anatomo-clinical pathological entities. Thus, its painful symptoms vary greatly in its location and intensity. MRI, the reference examination for diagnosis but operator dependent, shows imperfect sensitivity. The diagnosis and characterization of lesions must therefore be improved. We know that 17β-estradiol, a key hormone for lesion growth, can also be produced locally by endometriotic tissue. The hypothesis according to which this local accumulation of estrogens plays an important role in the development of lesions by modulating the expression of RE must be studied. The use of new tools to study estrogen receptor expression should be evaluated at diagnosis. A new examination, [18F]-FES PET/CT, could on the one hand improve diagnosis by showing greater sensitivity than MRI and on the other hand make it possible to quantify and characterize the expression of the ER from the diagnosis and thus help to guide therapeutic care. [18F]-FES PET/CT is a non-invasive, operator-independent method that visualizes and quantifies ER expression in multiple tumors. Some studies have shown that [18F]-FES uptake correlates well with ER expression measured by immunohistochemistry staining. We will thus attempt to correlate the intensity of [18F]-FES PET/CT with the expression of estrogen receptors and the intensity of pain.

03

Conditions studied

  • Endometriosis

Keywords

  • Endometriosis
  • Estrogen receptors
  • Pain
  • [18F]-FES PET/CT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cases:

- Painful patients with a VAS ≥ 4 treated surgically for painful symptoms related to endometriosis;

Controls:

  • Patient with a VAS \< 4 treated surgically for endometriosis in the context of infertility;
  • Age > 18 years;
  • Patient who provided ;
  • Patients who underwent a preoperative MRI and were not for [18F]-FES PET/CT;
  • Patient who underwent surgery mid-cycle;
  • Affiliation to a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Patient treated for endometriosis without surgery;
  • Pregnant patient
  • Patient taking hormone therapy
  • Menopausal patient
  • to the active substance (Fluoroestradiol (18F)) or to any of the
  • Patient under legal protection
  • Claustrophobic patient
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Endometriosis Patients Undergoing Surgery for Severe Pain Management (EVA ≥ 4)

    Procedure: Preoperative [18F]-FES PET/CT Imaging and Estrogen Receptor Expression Analysis in Endometriosis Surgery

  • Experimental
    Endometriosis Patients Undergoing Surgery for Infertility Without Severe Pain (EVA < 4)

    Procedure: Preoperative [18F]-FES PET/CT Imaging and Estrogen Receptor Expression Analysis in Endometriosis Surgery

Interventions

  • ProcedurePreoperative [18F]-FES PET/CT Imaging and Estrogen Receptor Expression Analysis in Endometriosis Surgery

    This study includes preoperative \[18F\]-FES PET/CT imaging to assess estrogen receptor expression in endometriosis patients undergoing laparoscopic or robot-assisted surgery. Pain levels will be evaluated using VAS, BPI, HADS, and SF-36 scales. Immunohistochemistry and quantitative mRNA expression analysis (ESR1, ESR2, GPER) will be performed on excised lesions using Tissue Microarray. This approach aims to correlate PET/CT imaging findings with histological and molecular data, distinguishing it from standard surgical interventions.

06

What researchers measure

Primary outcomes

  1. Quantification of Estrogen Receptor Overexpression in Endometriotic Lesions Using SUV on [18F]-FES PET/CT

    Estrogen receptor (ER) overexpression in endometriotic lesions will be assessed using the Standardized Uptake Value (SUV) on preoperative \[18F\]-FES PET/CT imaging. Each lesion's SUV will be quantified and compared within patients and between groups with high pain levels (VAS ≥ 4) and low or no pain (VAS \< 4). ER overexpression is defined as increased \[18F\]-FES uptake compared to background levels. The correlation between SUV values and pain severity will be analyzed to determine whether ER overexpression is associated with symptomatic burden. Higher SUV values indicate greater ER expression.

    Time frame: Preoperative assessment at mid-cycle, before surgery and without concurrent hormonal treatment.

Secondary outcomes

  1. Characterization of Lesion Staining by Immunohistochemistry and In Situ Hybridization: Intensity and Receptor Expression by Anatomical Location.

    Lesions were analyzed using immunohistochemistry (IHC) and in situ hybridization to characterize receptor expression patterns (ERα, ERβ, GPER) and staining intensity. Tissue microarrays (TMA) from 20 patients were used to standardize analysis. IHC staining was performed with specific antibodies against ERα (SP1) and ERβ (CWK-F12 (DSHB)), while in situ hybridization was conducted using Bio-Techne probes targeting ESR1, ESR2, and GPER mRNA. Staining intensity and receptor expression were assessed for each lesion and compared across anatomical locations. Correlation with \[18F\]-FES PET/CT imaging and clinical symptomatology was also evaluated.

    Time frame: From tissue collection at surgery to completion of immunohistochemical and in situ hybridization analyses (approximately 4 weeks post-surgery).

  2. Sensitivity of [18F]-FES PET/CT Compared to MRI for Diagnosing Superficial and Deep Endometriotic Lesions by Anatomical Location.

    The sensitivity of \[18F\]-FES PET/CT in detecting superficial and deep endometriotic lesions will be compared to that of MRI. Lesions will be classified based on their anatomical location. Sensitivity will be calculated as the proportion of true positive lesions detected by each imaging modality, using surgical and histopathological findings as the reference standard. The diagnostic performance of PET/CT and MRI will be analyzed for different lesion types and locations to assess their respective accuracy in detecting endometriosis.

    Time frame: From completion of MRI and [18F]-FES PET/CT imaging (performed within 4 weeks prior to surgery) to histopathological analysis of lesions obtained during surgery (within 4 weeks post-imaging); total assessment period: up to 8 weeks per participant

  3. Association Between [18F]-FES SUV Intensity, Estrogen Receptor Expression (IHC), and Pain Severity (VAS Score)

    The association between \[18F\]-FES standardized uptake value (SUV) intensity, estrogen receptor (ER) expression assessed by immunohistochemistry (IHC), and pain severity will be analyzed. ER expression will be evaluated using specific antibodies for ERα and ERβ, and quantified based on staining intensity. Pain severity will be assessed using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst possible pain). Correlations will be determined to assess the relationship between tracer uptake, receptor expression, and pain perception

    Time frame: From the date of [18F]-FES PET/CT imaging (≤4 weeks before surgery) to the date of surgery and completion of pain assessments (VAS and BPI) and histopathological analysis of surgical samples; total duration of assessment per participant : up to 8 weeks

  4. Correlation Between Estrogen Receptor Expression in IHC/ISH and Pain Intensity (VAS) in Endometriosis

    Estrogen receptor expression (ERα, ERβ, GPER) will be assessed in endometriotic lesions using immunohistochemistry (IHC) and in situ hybridization (ISH). Staining intensity will be scored semi-quantitatively (e.g., 0 to 3). Pain severity will be measured using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst possible pain). A correlation analysis will be conducted to evaluate the relationship between receptor expression scores and VAS scores. The unit of measure will be the correlation coefficient between IHC/ISH scores and VAS units (0-10 scale).

    Time frame: From surgery (biopsy collection) to completion of pain assessment and histological analysis; up to 8 weeks.

  5. Correlation Between Estrogen Receptor mRNA Expression and Pain Intensity (VAS) in Endometriosis

    Estrogen receptor mRNA expression (ESR1, ESR2, GPER) will be quantified in endometriotic lesions using in situ hybridization (ISH). Expression levels will be evaluated based on signal intensity scores derived from probe hybridization. Pain severity will be measured using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst pain). A statistical correlation will be assessed between the mRNA expression signal intensity scores and VAS values. The unit of measure will be the correlation coefficient quantifying the relationship between receptor expression levels and reported pain intensity.

    Time frame: From surgery (biopsy collection) to completion of ISH and VAS assessments; up to 8 weeks.

07

Study locations

1 of 1 sites recruiting
  • Toulouse, Rangueil Hospital
    Toulouse, 65360, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.

Of 199 non-industry interventional studies with no phase under Endometriosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 44. This study's planned 24 months is close to that.

Counting every sponsor, half of 214 studies reached it within 25 months; a quarter within 13 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2025
First posted
Jul 8, 2025
StartActual
Mar 23, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07053982
Responsible party
Sponsor
First posted
Jul 8, 2025
Start date
Mar 23, 2026
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Mar 25, 2026

Study contacts

Ariane Weyl
Contact
weyl.a@chu-toulouse.fr
05 61 32 21 48 ext. +33
Caroline Peyrot
Contact
peyrot.c@chu-toulouse.fr
+33 (0)5 61 77 84 86 ext. +33
Ariane WEYL, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion